Understanding how mutations in ZFP36L2 affect colorectal cancer progression and immune response
Dissecting the Functional Consequences of Mutations in ZFP36L2 on Tumor Progression and Inflammation in the Tumor Immune Microenvironment of Colorectal Cancer
This study is looking at how changes in a specific gene called ZFP36L2 might affect the growth of colorectal cancer and the way the immune system interacts with these tumors, with the hope of finding better treatment options for patients whose cancer doesn't respond well to current therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10996700 on NIH RePORTER |
What this research studies
This research investigates the role of ZFP36L2 mutations in colorectal cancer (CRC) and how these mutations influence tumor progression and the immune environment. By using advanced mouse models, the study aims to explore how the loss of ZFP36L2 function can lead to increased immune cell infiltration in tumors that typically do not respond well to current immunotherapies. The goal is to identify new targets and biomarkers that could improve treatment options for patients with microsatellite stable (MSS) colorectal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with microsatellite stable (MSS) colorectal cancer, particularly those with advanced disease.
Not a fit: Patients with microsatellite unstable (MSI) colorectal cancer may not benefit from this research as they typically respond better to existing immunotherapies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the effectiveness of immunotherapy for a larger group of colorectal cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting immune responses in colorectal cancer, but this specific approach focusing on ZFP36L2 mutations is relatively novel.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Luckett, Kathleen — Weill Medical Coll of Cornell Univ
- Study coordinator: Luckett, Kathleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.